Pfizer: Growth From Oncology Franchise; Initiate With 'Buy'

Pfizer (NYSE: PFE ) has been strategically increasing their business exposure in the oncology franchise by developing more cancer drugs to drive their future growth. I think the acquisition of Seagen could strengthen their Antibody-Drug Conjugate (ADC) technology. I am initiating with a 'Buy' rating withMore than 15 years of professional investment experience in global equities across all sectors. My investment style is fundamental, bottom-up, long-term, and quality growth-oriented. I am seeking companies s ...